CVRx, Inc., a Minneapolis, MN-based medical device company, has completed a $29.6m private equity financing.
The round was co-led by New Enterprise Associates and Johnson & Johnson Development Corporation with participation from existing investors BBT Fund L.P. and SightLine Partners.
CVRx intends to use the funding to advancing its clinical trials and expand its international commercial activities.
Founded in 2001 and led by Nadim Yared, President and Chief Executive Officer, and Robert Kieval, Executive Vice President and Chief Technology Officer, CVRx has developed the Barostim neo™, an implantable system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States and under clinical evaluation for the treatment of hypertension in the United States.
FinSMEs
11/07/2013